SCYNEXIS (SCYX) announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SCYNEXIS continues to meet all other continued listing criteria for the Nasdaq Capital Market.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCYX:
- SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path
- Scynexis completes transfer of BREXAFEMME NDA to GSK
- Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration
- SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating
- SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates